Aurelia Baures

Aurelia Baures

Auto-generated profile, based on publicly available information

Aurelia Baures

METHYSDx, Paris, France

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
GBGuillaume Beinse
Guillaume Beinse
VTValérie Taly
Valérie Taly
ALAlexandra Leary
Alexandra Leary
ABAurelia Baures
Aurelia Baures
IRIsabelle Ray-Coquard
Isabelle Ray-Coquard
JAJérôme Alexandre
Jérôme Alexandre
Purpose: ctDNA may offer a noninvasive means to evaluate tumor response and anticipate disease dynamics before radiologic changes in advanced endometrial carcinoma. Experimental Design: This ancillary analysis included patients from the multicenter, randomized, phase II GINECO-UTerin OLAparib (UTOLA) trial (NCT03745950) evaluating olaparib/placebo as maintenance after first-line platinum-based chemotherapy. Plasma samples were collected at screening after chemotherapy (baseline), 3 months (M3), and progression. ctDNA detection was assessed by a validated methylation-based Droplet Digital PCR (MethddPCR) assay targeting DNA positions universally methylated in endometrial carcinoma. Results: Among 130 evaluable patients, ctDNA was detected in 25 of 129 (19%, 1 technical fail) at baseline, 15 of 80 (19%) at M3, and 33 of 52 (63%) at progression. Baseline ctDNA positivity was independently associated with poorer progression-free survival (PFS) [median 1.81 vs. 7.39 months; adjusted HR = 5.33 (3.17–8.97)] and overall survival (OS) [10.3 vs. 24.7 months; adjusted HR = 3.98 (2.28–6.91); adjusted for age, stage IV at diagnosis, p53abn subgroup, and residual measurable lesions after chemotherapy]. Patients with baseline ctDNA had median OS of 9.36 months under olaparib versus 19.6 months under placebo (log-rank P = 0.05). Patients with increasing ctDNA at M3 had median PFS of 1.67 months, versus 9.64 months without, and median OS of 18.8 versus 25.8 months. ctDNA rising was predictive of poor postprogression OS under olaparib but not under placebo (interaction test, P < 0.001). Conclusions: MethddPCR-ctDNA is an independent prognostic biomarker for OS in advanced/metastatic endometrial carcinoma. MethddPCR-ctDNA may identify patients unlikely to benefit from PARP inhibition, guide therapeutic decisions, and should be further evaluated as a new stratification parameter in future endometrial carcinoma trials.


1 April 2026
Verified
Other
Open access
GBGuillaume Beinse
Guillaume Beinse
VTValérie Taly
Valérie Taly
ALAlexandra Leary
Alexandra Leary
ABAurelia Baures
Aurelia Baures
IRIsabelle Ray-Coquard
Isabelle Ray-Coquard
JAJérôme Alexandre
Jérôme Alexandre
Figure S7. Association between ctDNA detection after chemotherapy and nLST. nLST: number of large-scale transitions as per GIScar (see method – surrogate of homologuous repair deficiency-associated genomic scars)

1 April 2026
Verified
Other
Open access
GBGuillaume Beinse
Guillaume Beinse
VTValérie Taly
Valérie Taly
ALAlexandra Leary
Alexandra Leary
ABAurelia Baures
Aurelia Baures
IRIsabelle Ray-Coquard
Isabelle Ray-Coquard
JAJérôme Alexandre
Jérôme Alexandre
Figure S8. Association between olaparib treatment and survival according to ctDNA clearance, p53 molecular group, nLST, and stage I-III at diagnostic. Kaplan-Meir curves. OLA: olaparib. PLA: placebo. p value as per log-rank test.

1 April 2026
Verified
Other
Open access
GBGuillaume Beinse
Guillaume Beinse
VTValérie Taly
Valérie Taly
ALAlexandra Leary
Alexandra Leary
ABAurelia Baures
Aurelia Baures
IRIsabelle Ray-Coquard
Isabelle Ray-Coquard
JAJérôme Alexandre
Jérôme Alexandre
Figure S9. Association between ctDNA and PFS1. Regression curve fitted as y = log (x).

1 April 2026
Verified
Other
Open access
GBGuillaume Beinse
Guillaume Beinse
VTValérie Taly
Valérie Taly
ALAlexandra Leary
Alexandra Leary
ABAurelia Baures
Aurelia Baures
IRIsabelle Ray-Coquard
Isabelle Ray-Coquard
JAJérôme Alexandre
Jérôme Alexandre
Figure S1. Flow overview. ctDNA: circulating tumor DNA. C1-C6 : figure cycle 1 to cycle 6 of first line chemotherapy.